← Human Trials & Peer-Reviewed Studies
Intra-arterial methylene blue injection into ex vivo colorectal cancer specimens improves lymph node staging accuracy: a randomized controlled trial
Plain-language guide to PMID 24911342 (2014): randomized controlled trial study of Methylene blue (non-peptide stack partner).
Key Facts
- PMID
- 24911342
- Journal
- Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland
- Year
- 2014
- Study type
- Randomized Controlled Trial
- Authors
- Borowski DW et al. (9 authors)
- DOI
- 10.1111/codi.12681
What This Study Did, in Plain Language
What Was Tested
This randomized controlled trial paper looks at Methylene blue (non-peptide stack partner).
A randomized controlled trial was carried out to study the effect of a recently proposed technique of ex vivo intra-arterial methylene blue injection of the surgical specimen removed for colorectal cancer on lymph node harvest and staging.
Who Took Part
The age groups tagged for this paper are adults, middle-aged adults, older adults and people over 80, both men and women.
Between May 2012 and February 2013, 100 consecutive colorectal cancer resection specimens in a single institution were randomly assigned to intervention (methylene blue injection) and control (standard manual palpation technique) groups before formalin fixation.
The specimen was then examined by the histopathologist for lymph nodes.
How the Study Was Run
The researchers set it up as a randomized study.
Because people in this Methylene blue (non-peptide stack partner) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.
What Was Measured
PubMed files the paper under topics including Abdomen, Colorectal Neoplasms, Coloring Agents, Injections, Lymph Node Excision, Lymph Nodes and Lymphatic Metastasis.
The authors tagged it with the keywords Colorectal cancer, lymph node harvest, methylene blue, randomized controlled trial and staging.
What This Means in Plain Language
The paper is a randomized study of Methylene blue (non-peptide stack partner).
Results are reported in around 6 sentences of the abstract; we leave them to the paper itself rather than summarise them.
The publication is from 2014 (Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland), a journal based in England.
More context: the Methylene blue (non-peptide stack partner) compound page, all human trials.
Our Notes on the Compound
Methylene blue (non-peptide stack partner): Described as an electron cycler, not just a dye.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.